Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients

American Journal of Kidney Diseases

Volumn 29, Issue 2, 1997, Pages 239-245

  Peces, Ramón ^a,b   De La Torre, Miguel ^a   Alcázar, Roberto ^a   Urra, José M ^a  

^a Hospital Alarcos   (Spain)

^b NONE   (Spain)

Author keywords

Aged; hemodialysis; hepatitis B vaccine; hepatitis C; HLA DR7; HLA A2; HLA DQ2; HLA DR3; nonresponder; rHuEPO

Indexed keywords

HEPATITIS B VACCINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; HEMODIALYSIS; HEPATITIS B; HLA SYSTEM; HUMAN; INFECTION PREVENTION; INFECTIOUS COMPLICATION; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; SEROCONVERSION;

EID: 0030941090     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(97)90036-6     Document Type: Article

References (36)

1. Bruguera M, Cremades M, Rodicio JL, Alcazar JM, Oliver A, Del Rio G, Esteban-Mur R: Immunogenicity of a yeast-derived hepatitis B vaccine in hemodialysis patients. Am J Med 87:S30-S32, 1989
2. Alper CA, Kruskall MS, Marcus-Bagley D, Craven DE, Katz AJ, Brink SJ, Dienstag JL, Awdeh Z, Yunis EJ: Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 321:708-712, 1989
3. Pol S, Legendre C, Mattlinger B, Berthelot P, Kreis H: Genetic basis of nonresponse to hepatitis B vaccine in hemodialyzed patients. J Hepatol 11:385-387, 1990
4. Fleming SG, Moran DM, Cooksley WG, Faoagali JL: Poor response to a recombinant hepatitis B vaccine in dialysis patients. J Infect 22:251-257, 1991
5. Sennesael JJ, Van Der Niepen P, Verbeelen DL: Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int 40:121-128, 1991
6. Navarro JF, Teruel JL, Mateos M, Ortuño J: Hepatitis C virus infection decreases the effective antibody response to hepatitis B vaccine in the hemodialysis patients. Clin Nephrol 41:113-116, 1994
7. Quiroga JA, Castillo I, Porres JC, Casado S, Sáez F, Gracia-Martínez M, Gómez M, Inglada L, Sánchez-Sicilia L, Mora A: Recombinant interferon as adjuvant to hepatitis B vaccine in hemodialysis patients. Hepatology 12:661-663, 1990
8. Varla-Leftherioti M, Papanicolaou M, Spyropoulou M, Vallindra H, Tsiroyianni P, Tassopoulos N, Kapasouri H, Stavropoulos-Giokas C: HLA-associated non-responsiveness to hepatitis B vaccine. Tissue Antigens 35:60-63, 1990
9. Caillat-Zucman S, Gimenez JJ, Albouze G, Lebkiri B, Naret C, Jungers P, Bach JF: HLA genetic heterogeneity of hepatitis B vaccine response in hemodialyzed patients. Kidney Int 43:8157-8160, 1993 (suppl 41)
10. Stachowski J, Pollok M, Barth C, Maciejewski J, Baldamus CA: Non-responsiveness to hepatitis B vaccination in haemodialysis patients: Association with impaired TCR/CD3 antigen receptor expression regulating co-stimulatory processes in antigen presentation and recognition. Nephrol Dial Transplant 9:144-152, 1994
11. Terasaki PI, McClelland JD: Microdroplet assay of human serum cytotoxins. Nature 204:998-1000, 1964
12. Marangi AL, Giordano R, Montanaro A, De Padova F, Schiavone MG, Dongiovanni G, Basile C: Hepatitis B virus infection in chronic uremia: Long-term follow-up of a two-step integrated protocol of vaccination. Am J Kidney Dis 23:537-542, 1994
13. El Reshaid K, Al Mufti S, Johny KV, Sugathan TN: Comparison of two immunization schedules with recombinant hepatitis B vaccine and natural immunity acquired by hepatitis B infection in dialysis patients. Vaccine 12:223-234, 1994
14. Stachowski J, Kramer J, Fust G, Maciejewski J, Baldamus CA, Petranyi GG: Relationship between the reactivity to hepatitis B virus vaccination and the frequency of MHC class I, II and III alleles in haemodialysis patients. Scand J Immunol 42:60-65, 1995
15. Kimata H, Yoshida A, Ishioka C, Masuda S, Sasaki R, Mikawa H: Human recombinant erythropoietin directly stimulates B cell immunoglobulin production and proliferation in serum-free medium. Clin Exp Immunol 85:151-156, 1991
16. Kimata H, Yoshida A, Ishioka C, Mikawa H: Erythropoietin enhances immunoglobulin production and proliferation by human plasma cells in a serum-free medium. Clin Immunol Immunopathol 59:495-501, 1991
17. Grimm PC, Sinai-Trieman L, Sekiya NM, Robertson LS, Robinson BJ, Fine RN, Ettenger RB: Effects of recombinant human erythropoietin on HLA sensitization and cell mediated immunity. Kidney Int 38:12-18, 1990
18. Deierhoi MH, Barger BO, Hudson SL, Shroyer TW, Diethelm AG: The effect of erythropoietin and blood transfusions on highly sensitized patients on a single cadaver renal allograft waiting list. Transplantation 53:363-368, 1992
19. Peces R, Urra JM, de la Torre M: Influence of HLA-DR phenotype on tumor necrosis factor alpha (TNFα) production in renal transplant recipients. Nephron 71:180-183, 1995
20. Girndt M, Köhler H, Schiedhelm-Weick E, Schlaak JF, Meyer zum Büschenfelde KH, Fleischer B: Production of interleukin-6, tumor necrosis factor a and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int 47:559-565, 1995
21. Germain RN: MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation. Cell 76:287-299, 1994
22. Milich DR, Leroux-Roels GG, Louie RE, Chisari FV: Genetic regulation of the immune response to the hepatitis B surface antigen (HBsAg). IV. Distinct H-2-linked Ir genes control antibody responses to different HBsAg determinants on the same molecule and map to the I-A and I-C subrogions. J Exp Med 159:41-56, 1984
23. Celis E, Karr RW: Presentation of an immunodominant T-cell epitope of hepatitis B surface antigen by the HLA-DPw4 molecule. J Virol 63:747-752, 1989
24. Desombere I, Hauser P, Rossau R, Paradijs J, Leroux-Roels G: Nonresponders to hepatitis B vaccine can present envelope particles to T lymphocytes. J Immunol 154:520-529, 1995
25. Hervás-Stubbs S, Berasain C, Golvano JJ, Lasarte JJ, Prieto I, Sarobe P, Prieto J, Borrás-Cuesta F: Overcoming class II-linked non-responsiveness to hepatitis B vaccine. Vaccine 12:867-871, 1994
26. Barnaba V, Franco A, Alberti A, Benbenuto R, Balsano F: Selective killing of hepatitis B envelope antigen-specific B cells by class I-restricted, exogenous antigen-specific T lymphocytes. Nature 345:258-260, 1990
27. Bertoletti A, Ferrari C, Fiaccadori F, Penna A, Margolskee R, Schlicht HJ, Fowler P, Guilhot S, Chisari FV: HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci U S A 88:10445-10449, 1991
28. Nayersina R, Fowler P, Guilhot S, Missale G, Cerny A, Schlicht HJ, Vitiello A, Chesnut R, Person JL, Redeker AG, Chisari FV: HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 150:2659-4671, 1993
29. Vitiello A, Ishioka G, Grey HM, Rose R, Farness P, LaFond R, Yuan L, Chisari FV, Furze J, Bartholomeuz R, Chesnut RW: Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 95:341-349, 1995
30. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, Melief CJM, Oseroff C, Yuan L, Ruppert J, Sidney J, del Guercio MF, Southwood S, Kubo RT, Chesnut RW, Grey HM, Chisari FV: The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 153:5586-5592, 1994
31. Steketee RW, Ziarnik ME, Davis JP: Seroresponse to hepatitis B vaccine in patients and staff of renal dialysis centers. Wisconsin. Am J Epidemiol 127:772-782, 1988
32. Girndt M, Köhler H, Schiedhelm-Weick E, Meyer zum Büschenfelde KH, Fleischer B: T cell activation in hemodialysis patients: Evidence for a role of the B7/CD28 pathway. Kidney Int 44:359-365, 1993
33. Chang PC, Schrander-van der Meer AM, van Dorp WT, van Leer E: Intracutaneous versus intramuscular hepatitis B vaccination in primary non-responding haemodialysis patients. Nephrol Dial Transplant 11:191-193, 1996
34. Meuer S, Dumann H, Meyer zum Büschenfelde KH, Köhler H: Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet i:15-18, 1989
35. Jungers P, Devillier P, Salomon H, Cerisier JE, Courouce AM: Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine. Lancet 344:856-857, 1994
36. Haubitz M, Ehlerding G, Beigel A, Heuer U: Clinical experience with a new recombinant hepatitis-B vaccine in previous non-responders with chronic renal insufficiency. Clin Nephrol 45:180-182, 1996